PIM1 and prostate adenocarcinoma: Our results indicate that PIM-1 is overexpressed at a high frequency in EpCAM(+) CTC fraction in mCRPC (37.5%), when compared to the TCGA data in prostate adenocarcinoma primary tumors (6%).